SLAM
CRSP icon

Swiss Life Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Swiss Life Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$324K Buy
+5,939
New +$313K ﹤0.01% 1217
2025
Q4 		– Sell
-3,761
Closed -$244K – 1390
2025
Q3 		$244K Buy
+3,761
New +$216K ﹤0.01% 1020

Other funds holding CRSP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Swiss Life Asset Management's CRSP Position: Q2 2026 in Review

Swiss Life Asset Management opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 5,939 shares worth $324K. The stake represents ﹤0.01% of the portfolio and ranks #1217 among its holdings. This is a return to the name: Swiss Life Asset Management previously reported a position in CRSP as recently as Q3 2025.

Swiss Life Asset Management first reported a position in CRSP in Q3 2025 and has held it in 2 quarters since. 384 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Swiss Life Asset Management held 5,939 shares of CRISPR Therapeutics worth $324K as of Q2 2026.
  • CRISPR Therapeutics was a new Swiss Life Asset Management position in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #1217 holding.
  • Swiss Life Asset Management first reported a position in CRISPR Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 384 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.